3.050USD+0.69%Mkt Cap: 6.99M USDP/E: —Last update: 2026-05-26
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap6.99M USD
Enterprise Value-610.10K USD
Revenue (TTM)3.19M USD
Gross Profit3.19M USD
Net Income (TTM)-2.68M USD
Revenue/Share1.689 USD
Last Price3.050 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.45
PEG—
EV/EBITDA—
EV/Revenue-0.19
P/S2.11
P/B0.91
EPS (TTM)-1.19
EPS (Forward)-0.66
52W Range
1.90010% of range13.93
52W High13.93 USD
52W Low1.900 USD
Profitability
Gross Margin100.00%
Oper. Margin-62.23%
EBITDA Margin0.00%
Profit Margin-90.07%
ROE-36.25%
ROA-32.05%
Growth
Revenue Growth36.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.29M USD
CapEx (TTM)—
FCF Margin-33.71%
FCF Yield-15.39%
Net Debt-7.35M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio7.93
Quick Ratio7.67
Book Value/Sh3.227 USD
Cash/Share3.207 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 25, 2019
Splits
Last Split1:10
Split DateMay 15, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.29M
Float1.78M
Insiders10.24%
Institutions7.68%
Short Interest
Short Ratio0.5d
Short % Float0.33%
Short % Out.0.32%
Shares Short7.27K
Short (prev mo.)20.60K
Technical
SMA 503.061 (-0.4%)
SMA 2002.923 (+4.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)13.83K
Avg Vol (10d)7.83K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—